Herein, we will examine the role of CD4+ T cells in tumor immunity (Figure 5), new discoveries of potent subsets within the CD4+ lineage, and clinical implications of engineering human CD4+ T cell subsets with CAR-specificity to extend treatment outcomes. This evidence concerns the gene CD4 and neoplasm.